The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter
Abstract
BACKGROUND: The optimal upper limit of the normal range for prostate-specific antigen (PSA) is unknown. We investigated the prevalence of prostate cancer among men in the Prostate Cancer Prevention Trial who had a PSA level of 4.0 ng per milliliter or less. METHODS: Of 18,882 men enrolled in the prevention trial, 9459 were randomly assigned to receive placebo and had an annual measurement of PSA and a digital rectal examination. Among these 9459 men, 2950 men never had a PSA level of more than 4.0 ng per milliliter or an abnormal digital rectal examination, had a final PSA determination, and underwent a prostate biopsy after being in the study for seven years. RESULTS: Among the 2950 men (age range, 62 to 91 years), prostate cancer was diagnosed in 449 (15.2 percent); 67 of these 449 cancers (14.9 percent) had a Gleason score of 7 or higher. The prevalence of prostate cancer was 6.6 percent among men with a PSA level of up to 0.5 ng per milliliter, 10.1 percent among those with values of 0.6 to 1.0 ng per milliliter, 17.0 percent among those with values of 1.1 to 2.0 ng per milliliter, 23.9 percent among those with values of 2.1 to 3.0 ng per milliliter, and 26.9 percent among those with values of 3.1 to 4.0 ng per milliliter. The prevalence of high-grade cancers increased from 12.5 percent of cancers associated with a PSA level of 0.5 ng per milliliter or less to 25.0 percent of cancers associated with a PSA level of 3.1 to 4.0 ng per milliliter. CONCLUSIONS: Biopsy-detected prostate cancer, including high-grade cancers, is not rare among men with PSA levels of 4.0 ng per milliliter or less--levels generally thought to be in the normal range.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Influence of Finasteride on the Development of Prostate Cancer
Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030660 · Cited by 2,518
Self-citationMeasurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer
Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J., Petros, J. A., & Andriole, G. L. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104253241702 · Cited by 2,361
Sathianathen, N. (2021) · 50 Studies Every Urologist Should Know · doi:10.1093/med/9780190655341.003.0002 · Cited by 2,080
Phases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686
Purification of a Human Prostate Specific Antigen
Wang, M. C., Valenzuela, L. A., Murphy, G. P., & Chu, T. M. (2017) · Journal of Urology · doi:10.1016/j.juro.2016.10.100 · Cited by 825
Cooner, W. H., Mosley, B. R., Rutherford, C. L., Beard, J. H., Pond, H. S., Terry, W. J., Igel, T. C., & Kidd, D. D. (1990) · Journal of Urology · doi:10.1016/s0022-5347(17)40211-4 · Cited by 767
Albertsen, P. C. (1998) · JAMA · doi:10.1001/jama.280.11.975 · Cited by 717
Screening for Prostatic Carcinoma with Prostate Specific Antigen
Brawer, M. K., CHETNER, M. P., Beatie, J., Büchner, D. M., Vessella, R. L., & Lange, P. H. (1992) · The Journal of Urology · doi:10.1016/s0022-5347(17)37401-3 · Cited by 612
Gohagan, J. K., Prorok, P. C., Hayes, R. B., & Kramer, B.-S. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00097-0 · Cited by 544
Punglia, R. S., D'Amico, A. V., Catalona, W. J., Roehl, K. A., & Kuntz, K. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021659 · Cited by 326
Catalona, W. J., Hudson, M. A., Scardino, P. T., Richie, J. P., Ahmann, F. R., Flanigan, R. C., deKernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., et al. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)32300-5 · Cited by 316
Lee, F., McLeary, R. D., Kumasaka, G. H., Borlaza, G. S., Straub, W. H., Gray, J. M., Meadows, T. R., Lee, F., Solomon, M. H., McHugh, T. A., et al. (1985) · The Prostate · doi:10.1002/pros.2990070202 · Cited by 237
Krumholtz, J. S., Carvalhal, G. F., Ramos, C. G., Smith, D. S., Thorson, P., Yan, Y., Humphrey, P. A., Roehl, K. A., & Catalona, W. J. (2002) · Urology · doi:10.1016/s0090-4295(02)01875-7 · Cited by 170
Serum Prostatic Antigen Measurement in Localized Prostatic Cancer: Correlation with Clinical Course
Pontes, J. E., Chu, T. M., Slack, N. H., Karr, J., & Murphy, G. P. (1982) · The Journal of Urology · doi:10.1016/s0022-5347(17)53431-x · Cited by 64
Ultrasound-guided prostate biopsy Biopty gun superior to aspiration
Ragde, H., Aldape, H. C., & Bagley, C. M. (1988) · Urology · doi:10.1016/s0090-4295(98)90029-2 · Cited by 60
Biomarker-based methods for determining noncompliance in a prevention trial
Ankerst, D. P., Gower, K. B., Goodman, P. J., et al. (2002) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00231-3 · Cited by 11
Self-citation
Research works printed but not linked: 16
- Wang MC, 1979, Invest Urol, 17, 159
- Brawley OW, 1998, Semin Urol Oncol, 16, 187
- 10.1002/(SICI)1097-0045(19990201)38:2<83::AID-PROS1>3.0.CO;2-B · DOI
- Thompson IM, 2003, World J Urol, 21, 28, 10.1007/s00345-002-0315-y · doi:10.1007/s00345-002-0315-y
- 10.1111/j.1464-410X.1987.tb09137.x · doi:10.1111/j.1464-410x.1987.tb09137.x
- Kuriyama M, 1980, Cancer Res, 40, 4658
- Liedtke RJ, 1984, Clin Chem, 30, 649, 10.1093/clinchem/30.5.649 · doi:10.1093/clinchem/30.5.649
- Yang N, 1984, Clin Chem, 30, 1057
- 10.1016/0090-4295(86)90146-9 · doi:10.1016/0090-4295(86)90146-9
- Kuriyama M, 1982, J Natl Cancer Inst, 68, 99
- Thompson IM, 1984, J Urol, 132, 690, 10.1016/S0022-5347(17)49828-4 · doi:10.1016/s0022-5347(17)49828-4
- Ruebush TK II, 1979, J Urol, 122, 492, 10.1016/S0022-5347(17)56477-0 · doi:10.1016/s0022-5347(17)56477-0
- 10.1016/S0022-5347(01)63951-X · doi:10.1016/s0022-5347(01)63951-x
- 10.1016/S0090-4295(96)00091-X · doi:10.1016/s0090-4295(96)00091-x
- 10.1093/jnci/90.16.1230 · doi:10.1093/jnci/90.16.1230
- 10.1016/S0140-6736(00)02269-8 · doi:10.1016/s0140-6736(00)02269-8
Cited by
EAU Guidelines on Prostate Cancer
Heidenreich, A., Aus, G., Bolla, M., Joniau, S., Matveev, V. B., Schmid, H. P., & Zattoni, F. (2008) · European Urology · doi:10.1016/j.eururo.2007.09.002 · Cited by 3,136
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.09.046 · Cited by 1,936
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00229 · Cited by 1,736
Metadata
- Authors
- Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., Crowley, J. J., & Coltman, C. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-05-27
- Volume
- 350
- Issue
- 22
- Pages
- 2239-2246
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140687262
- Cited by
- 2,446
- References
- 16
- FWCI
- 118.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.